Cat. No.: HY-100004

Fumarate hydratase-IN-1

20 Cited Publications

Customer Review

Based on 20 publication(s) in Google Scholar

Fumarate hydratase-IN-1 (compound 2) is a cell-permeable fumarate hydratase inhibitor. Fumarate hydratase-IN-1 has antiproliferative activity against several cancer cell lines with a mean IC₅₀ of 2.2 μM.

For research use only. We do not sell to patients.

Purity: 99.58%
CAS No.: 1644060-37-6
Formula: C₂₇H₃₀N₂O₄
Molecular Weight:446.54

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Fumarate hydratase-IN-1 Chemical Structure

CAS No.: 1644060-37-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (20)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Fumarate hydratase^[1]

In Vitro

Fumarate hydratase-IN-1 inhibits SW620, ACHN, HCT-116, PC3, and SK-MEL-28 cell lines with a mean IC₅₀ of 2.2 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1644060-37-6
Appearance Solid
Molecular Weight 446.54
Formula C₂₇H₃₀N₂O₄
Color Off-white to yellow
SMILES

O=C(OCC)[C@]1([C@H](CC(NC)=O)C2=O)C(N2CC(C=C3)=CC=C3C4=CC=CC=C4)=CCCC1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (20)

All RT-PCRIFWBHistological Imaging/Staining

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Malate initiates a proton-sensing pathway essential for pH regulation of inflammation. [Abstract]

2024 Dec 30;9(1):367. PMID: 39737965
Nature

Macrophage fumarate hydratase restrains mtRNA-mediated interferon production. [Abstract]

2023 Mar;615(7952):490-498. PMID: 36890227

Fumarate hydratase-IN-1 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Mar;615(7952):490-498. [Abstract]

Both Fumarate hydratase-IN-1 (FHIN1) and Dimethyl fumarate (DMF) treatment limit IFNβ-induced STAT1 and JAK1 phosphorylation in BMDMs.
Cell Metab

Lack of PCK1 in hepatic stellate cells causes liver fibrosis by fueling tricarboxylic acid cycle and increasing glycolysis. [Abstract]

2026 Feb 23:S1550-4131(26)00016-1. PMID: 41734768
Mol Cell

Mitochondrial fumarate inhibits Parkin-mediated mitophagy. [Abstract]

2025 Jun 19;85(12):2287-2302.e9. PMID: 40505663
Adv Sci (Weinh)

Amphiregulin and Epiregulin Confer Radioresistance in Esophageal Squamous Cell Carcinoma Through Oxidative Phosphorylation. [Abstract]

2025 Nov 9:e07524. PMID: 41208199
Nat Chem Biol

Fumarate suppresses B-cell activation and function through direct inactivation of LYN. [Abstract]

2022 Sep;18(9):954-962. PMID: 35710616
Small

High Throughput Confined Migration Microfluidic Device for Drug Screening. [Abstract]

2023 Apr;19(16):e2207194. PMID: 36634971
Pharmacol Res

Dimethyl fumarate inhibits necroptosis and alleviates systemic inflammatory response syndrome by blocking the RIPK1-RIPK3-MLKL axis. [Abstract]

2023 Mar:189:106697. PMID: 36796462

Fumarate hydratase-IN-1 purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2023 Mar:189:106697. [Abstract]

Fumarate hydratase-IN-1 (FHIN1, 6.25-25 μM; 1 h) attenuates TSI (2 h)-induced necroptosis in a dose-dependent manner in BMDMs.

Fumarate hydratase-IN-1 purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2023 Mar:189:106697. [Abstract]

Fumarate hydratase-IN-1 (FHIN1, 6.25-25 μM; 1 h) inhibits the RIPK1-RIPK3-MLKL signaling pathway in BMDMs after stimulation with TSI (2 h).
Cell Death Dis

Oncometabolite fumarate facilitates PD-L1 expression and immune evasion in clear cell renal cell carcinoma. [Abstract]

2025 Jun 3;16(1):432. PMID: 40461489

Fumarate hydratase-IN-1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Jun 3;16(1):432. [Abstract]

Fumarate hydratase-IN-1 (FHIN1, 20 μM, 24 h) upregulates the protein and mRNA levels of PD-L1 in RCC10 and RCC4 cells.
EMBO J

SUCLG1 restricts POLRMT succinylation to enhance mitochondrial biogenesis and leukemia progression. [Abstract]

2024 Jun;43(12):2337-2367. PMID: 38649537
J Transl Med

Rutaecarpine induces the differentiation of triple-negative breast cancer cells through inhibiting fumarate hydratase. [Abstract]

2023 Aug 18;21(1):553. PMID: 37592347
Aging Cell

Role of Succinate Dehydrogenase in Age-Related Th17 Inflammation. [Abstract]

2026 Apr;25(4):e70451. PMID: 41874464
Cell Rep

Allosterically inhibited PFKL via prostaglandin E2 withholds glucose metabolism and ovarian cancer invasiveness. [Abstract]

2023 Oct 12;42(10):113246. PMID: 37831605
JCI Insight

IFN-γ-induced trained immunity enhances killing of priority pathogens in healthy and genetically vulnerable individuals. [Abstract]

2026 Feb 10:e195866. PMID: 41665962
J Inflamm Res

Fumarate Hydratase Restrains mtDNA Attenuates LPS-Induced Acute Lung Injury Through cGAS-STING Pathways. [Abstract]

2025 Apr 21:18:5399-5413. PMID: 40291460

Fumarate hydratase-IN-1 purchased from MedChemExpress. Usage Cited in: J Inflamm Res. 2025 Apr 21:18:5399-5413. [Abstract]

Fumarate level in lung tissue after Fumarate hydratase-IN-1 (FHIN1, 50 mg/kg; i.p.; Single dose) treatment (n=6).

Fumarate hydratase-IN-1 purchased from MedChemExpress. Usage Cited in: J Inflamm Res. 2025 Apr 21:18:5399-5413. [Abstract]

Fumarate hydratase-IN-1 (FHIN1, 10-20 μM; 3 h). Typical JC-1 immunofluorescence staining and statistical results in THP-1.

Fumarate hydratase-IN-1 purchased from MedChemExpress. Usage Cited in: J Inflamm Res. 2025 Apr 21:18:5399-5413. [Abstract]

Fumarate hydratase-IN-1 (FHIN1, 10-20 μM; 3 h). Western blots for cGAS, STING, IRF3 and p-IRF3 (n=6).

Fumarate hydratase-IN-1 purchased from MedChemExpress. Usage Cited in: J Inflamm Res. 2025 Apr 21:18:5399-5413. [Abstract]

Fumarate hydratase-IN-1 (FHIN1, 50 mg/kg; i.p.; Single dose). Typical H&E staining for mice lung tissues.
J Asia Pac Entomol

2024 Dec.
bioRxiv

SPEND-hSRS imaging of fumarate uncovers mitochondrial metabolic heterogeneity. [Abstract]

2026 Apr 7:2026.04.03.716311. PMID: 41993415
bioRxiv

Oncometabolite fumarate impairs ATR-CHK1 signaling by succinating RPA1 in Fumarate Hydratase-deficient renal cell carcinoma cells. [Abstract]

2025 Dec 10:2025.12.08.692638. PMID: 41427347
Res Sq

2025 Feb 16.
Patent

US20250018019A1.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (111.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2394 mL

11.1972 mL

22.3944 mL

5 mM

0.4479 mL

2.2394 mL

4.4789 mL

10 mM

0.2239 mL

1.1197 mL

2.2394 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Takeuchi T et al. Identification of Fumarate Hydratase Inhibitors with Nutrient-Dependent Cytotoxicity. J Am Chem Soc, 2015 Jan 21, 137(2): 564-567. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2394 mL	11.1972 mL	22.3944 mL	55.9860 mL
	5 mM	0.4479 mL	2.2394 mL	4.4789 mL	11.1972 mL
	10 mM	0.2239 mL	1.1197 mL	2.2394 mL	5.5986 mL
	15 mM	0.1493 mL	0.7465 mL	1.4930 mL	3.7324 mL
	20 mM	0.1120 mL	0.5599 mL	1.1197 mL	2.7993 mL
	25 mM	0.0896 mL	0.4479 mL	0.8958 mL	2.2394 mL
	30 mM	0.0746 mL	0.3732 mL	0.7465 mL	1.8662 mL
	40 mM	0.0560 mL	0.2799 mL	0.5599 mL	1.3997 mL
	50 mM	0.0448 mL	0.2239 mL	0.4479 mL	1.1197 mL
	60 mM	0.0373 mL	0.1866 mL	0.3732 mL	0.9331 mL
	80 mM	0.0280 mL	0.1400 mL	0.2799 mL	0.6998 mL
	100 mM	0.0224 mL	0.1120 mL	0.2239 mL	0.5599 mL

Keywords

Fumarate hydratase-IN-1

20 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Fumarate hydratase-IN-1

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Glutamine Metabolism Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

TCA Cycle Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Fumarate hydratase-IN-1

Biological Activity

Chemical Information

Publications (20)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Fumarate hydratase-IN-1

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Glutamine Metabolism Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

TCA Cycle Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Fumarate hydratase-IN-1

Biological Activity

Chemical Information

Publications (20)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Fumarate hydratase-IN-1 Related Classifications

HY-100004 Related Classifications